AMEX · VTAK
Healthcare · Medical - Devices
$0.17
Down-$0.01 (-6.78%)
Updated Sep 11, 2026, 8:19 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VTAK closed at $0.17 after 20 trading sessions, down 43.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.17 | $0.1747 | $0.16 | $0.165 | 900.9K |
| Sep 9, 2026 | $0.1864 | $0.1928 | $0.1676 | $0.177 | 2.22M |
| Sep 8, 2026 | $0.2043 | $0.2043 | $0.192 | $0.192 | 656.47K |
| Sep 4, 2026 | $0.193 | $0.21 | $0.1899 | $0.21 | 882.24K |
| Sep 3, 2026 | $0.1973 | $0.202 | $0.1959 | $0.1966 | 541.88K |
| Sep 2, 2026 | $0.1992 | $0.2039 | $0.195 | $0.2007 | 975.33K |
| Sep 1, 2026 | $0.1985 | $0.2039 | $0.1954 | $0.1983 | 511.99K |
| Aug 31, 2026 | $0.20 | $0.2049 | $0.1971 | $0.2037 | 467.27K |
| Aug 28, 2026 | $0.2028 | $0.205 | $0.1952 | $0.2007 | 1.78M |
| Aug 27, 2026 | $0.205 | $0.2109 | $0.1861 | $0.2027 | 22.37M |
| Aug 26, 2026 | $0.208 | $0.2172 | $0.2036 | $0.209 | 954.29K |
| Aug 25, 2026 | $0.2057 | $0.2174 | $0.205 | $0.2101 | 1.11M |
| Aug 24, 2026 | $0.2042 | $0.2088 | $0.201 | $0.2088 | 406.28K |
| Aug 21, 2026 | $0.21 | $0.21 | $0.20 | $0.2093 | 449.3K |
| Aug 20, 2026 | $0.209 | $0.2122 | $0.2033 | $0.2104 | 1.02M |
| Aug 19, 2026 | $0.2068 | $0.2188 | $0.1889 | $0.2133 | 1.69M |
| Aug 18, 2026 | $0.228 | $0.2299 | $0.20 | $0.2229 | 3.46M |
| Aug 17, 2026 | $0.2494 | $0.2494 | $0.2262 | $0.228 | 3.59M |
| Aug 14, 2026 | $0.275 | $0.2858 | $0.27 | $0.28 | 766.97K |
| Aug 13, 2026 | $0.2749 | $0.29 | $0.2692 | $0.29 | 911.69K |
The latest Smart Investors Daily articles mentioning VTAK.
VTAK research
Company profile and research snapshot.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 21, 2026
Fly Flyte, Inc. ("FLYTE"), the Regional Air Mobility subsidiary of Catheter Precision, Inc. (NYSE American: VTAK), today announced a strategic partnership with Blade Urban Air Mobility ("Blade") designed
Benzinga · Feb 19, 2026
Catheter Precision sells atherectomy catheter tech to sharpen focus on electrophysiology growth.
Benzinga · Feb 19, 2026
Upfront cash payment following closing of $15,000A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring companyTen-year
Benzinga · Feb 17, 2026
Catheter Precision, Inc. (NYSE:VTAK) today announced a strategic minority investment in Fly Flyte, Inc. ("Flyte"), an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTAK.
